Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center

Abstract EN

During the multidisciplinary planning of postoperative therapy after breast cancer, borderline cases can arise with no clear rationale for or against adjuvant chemotherapy.

In 50 hormone- receptor-positive, Her2neu-negative carcinomas of the breast with no or only minimal lymph node involvement (max.

pT1a) we initiated an Oncotype DX® multigene assay in addition to the evaluation of usual parameters.

In the oncology conference a vote for or against chemotherapy was taken on the basis of the conventional criteria for decision-making before the test results were available.

The final recommendation was made after the multigene test.

In 32 breast carcinomas (64%) a low recurrence score could be documented, while 26 (32%) showed an intermediate RS and 3 (6%) showed a high RS.

In most cases the result of the test could validate the choice of therapy established using conventional criteria.

In 5 cases the initial recommendation for adjuvant therapy was revised, and in 3 cases chemotherapy was secondarily recommended after evaluation of the test results.

Conversely, in some cases a low or intermediate risk constellation did not argue against a recommendation for adjuvant chemotherapy.

Altogether, the results of our study do not indicate that a multigene assay should be used as a routine diagnostic tool.

Instead a thorough compilation and careful analysis of conventional parameters for therapeutic decision-making should take precedence, with special emphasis on histopathological and immunohistochemical results.

In selected cases, however, a multigene assay can be a useful tool in the deliberation for or against a therapeutic pathway.